Contraindicated in:
Use Cautiously in:
CV: hypotension (Hepzato only), peripheral edema, THROMBOEMBOLIC EVENTS (HEPZATO ONLY).
Derm: alopecia, pruritus, rash.
Endo: menstrual irregularities.
F and E: hypokalemia, hypophosphatemia.
GI: ↓ appetite, ↑ liver enzymes (Hepzato Kit only), abdominal pain, constipation, diarrhea, hyperbilirubinemia, mucositis, nausea, vomiting, hepatotoxicity.
GU: infertility.
Hemat: ↑ activated partial thromboplastin time, ↑ international normalized ratio, anemia, leukopenia, neutropenia, thrombocytopenia, HEMORRHAGE (HEPZATO ONLY).
Metab: hyperuricemia.
MS: ↑ troponin I, pain.
Neuro: dizziness, fatigue, headache, lethargy.
Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), SECONDARY MALIGNANCY.
Drug-Drug:
Multiple Myeloma (Palliative Treatment)
Renal Impairment
Multiple Myeloma (Conditioning Treatment)
Unresectable Hepatic Metastases in Patients with Uveal Melanoma
Alkeran, Evomela, Hepzato
Absorption: IV and intra-arterial administration results in complete bioavailability.
Distribution: Rapidly distributed to tissues.
Metabolism/Excretion: Rapidly metabolized in the bloodstream. Small amounts (10%) excreted unchanged by the kidneys.
Half-life: IV: 1.5 hr; Intra-arterial: 1.1 hr.
(effects on blood counts)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
IV | unknown | 23 wk | 45 wk |
Intra-arterial | unknown | 1013 days | 23 wk |
NDC Code*